A Phase I/IIa clinical trial of JAB-26766
Latest Information Update: 01 Sep 2023
At a glance
- Drugs JAB 26766 (Primary)
- Indications Small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jacobio Pharmaceuticals
- 31 Aug 2023 New trial record